GW Pharmaceuticals PLC- ADR GWPH shares are trading higher by $6.69 (8 percent) at $90 in Monday's session. The issue surged to $102.50 in pre-market trading when it was announced that Epidiolex had met an Endpoint in its Phase 3 trial.
However, the issue has succumbed to profit-taking in the regular session. After a higher open, it immediately peaked at $93.70 and began to move lower. It has continued to make new lows for the session, with the current one standing at $89.10. In order to fill the void in price action from Friday's session, it would need to reach $85.61.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
